

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康宁杰瑞

ALPHAMAB ONCOLOGY

ALPHAMAB ONCOLOGY

康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9966)

**VOLUNTARY ANNOUNCEMENT
JIANGSU ALPHAMAB PASSED ON-SITE INSPECTION
OF EU QUALIFIED PERSON**

This announcement is made by Alphamab Oncology (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (“**Jiangsu Alphamab**”), a wholly-owned subsidiary of the Company, has passed the on-site inspection of an European Union qualified person (the “**EU Qualified Person**”) on February 3, 2020.

The inspection is for the preparation of the reliable supply for global clinical trials and subsequent manufacturing for the commercialization of KN035 (an anti-PD-L1 recombinant humanized single domain antibody invented by the Group). The EU Qualified Person conducted a comprehensive, strict and systematic inspection mainly on the quality control system and facilities in the biopharmaceutical production base of Jiangsu Alphamab (“**Production Base**”) located at Suzhou Industrial Park, Suzhou Area of Jiangsu Pilot Free Trade Zone, China (“**Suzhou Industrial Park**”). The scope of the inspection covers production workshops, warehouses and related support systems in the BioBay in Suzhou Industrial Park, as well as the new warehouse and the quality control laboratory located at No. 175, Fangzhou Road, Suzhou Industrial Park.

The Production Base has successfully passed the on-site inspection of the Jiangsu Drug Administration of the People’s Republic of China and was granted the Pharmaceutical Production License. Having successfully passed the on-site inspection of the EU Qualified Person marked that the production, warehousing and related support system and quality control system of Jiangsu Alphamab have been further improved and its production capacity has been further expanded, laying a solid foundation for reliable supply for global clinical trials and subsequent manufacturing for the commercialization.

ABOUT KN035

KN035 is potentially the first subcutaneously injectable PD-L1 inhibitor worldwide, offering advantages in safety, convenience, compliance, access to patients not suitable for intravenous infusion. Invented by the Group and jointly developed with 3DMed, KN035 is currently undergoing a phase II clinical trial for deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) solid tumors and a phase III pivotal trial for biliary tract cancer (BTC) in China.

ABOUT THE COMPANY

The Company is a leading clinical-stage biopharmaceutical company in China with a fully-integrated proprietary biologics platform in bispecific and protein engineering. Differentiated in-house pipeline of the Company consists of eight oncology drug candidates, including four in the phase I-III clinical trial development stage. The Company has developed various technologies and platforms of antibody-based therapies for oncology treatment and expertise in this regard. Benefitting from our proprietary protein engineering platforms and structure-guided molecular modeling expertise, the Company is able to create a new generation of multi-functional bio-macromolecule new drugs that benefit patients globally.

Cautionary Statement required by Rule 18A.05 of the Listing Rules: The Company cannot guarantee that it will be able to develop, or ultimately market, KN035 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
Alphamab Oncology
Dr. XU Ting
Chairman and Executive Director

Hong Kong, February 7, 2020

As at the date of this announcement, the Board comprises Dr. XU Ting as the Chairman and Executive Director and Ms. LIU Yang as Executive Director, Mr. XU Zhan Kevin and Mr. QIU Yu Min as Non-executive Directors, and Dr. JIANG Hualiang, Mr. WEI Kevin Cheng and Mr. WU Dong as Independent Non-executive Directors.